Cargando…

Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors

In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as “untargetable”; today, we see the birth of new molecules that ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherri, Sara, Melocchi, Laura, Gandolfi, Laura, Rossi, Giulio, Zaniboni, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967356/
https://www.ncbi.nlm.nih.gov/pubmed/36836752
http://dx.doi.org/10.3390/life13020395
_version_ 1784897244083781632
author Cherri, Sara
Melocchi, Laura
Gandolfi, Laura
Rossi, Giulio
Zaniboni, Alberto
author_facet Cherri, Sara
Melocchi, Laura
Gandolfi, Laura
Rossi, Giulio
Zaniboni, Alberto
author_sort Cherri, Sara
collection PubMed
description In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as “untargetable”; today, we see the birth of new molecules that target one of the variants of the KRAS mutation, KRAS G12C, having a significant impact on the therapeutic options for other malignancies, such as metastatic lung cancer. This fundamental step forward has stimulated scientific research on other potential targets of KRAS, both indirect and direct, and combination treatments aiming to overcome the mechanisms of resistance to these drugs that decrease in efficacy in colorectal cancer. What was once a negative predictive marker of response to anti-EGFR drugs today has become a potential target for targeted treatments. In turn, the prognostic role of the mutation has become extremely interesting, making it a potentially useful element in therapeutic decision-making, not only regarding oncological treatments but also in a more complex and complete manner within a global vision of the patient, involving other figures on the multidisciplinary team, such as surgeons, radiotherapists, and interventional radiologists.
format Online
Article
Text
id pubmed-9967356
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99673562023-02-26 Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors Cherri, Sara Melocchi, Laura Gandolfi, Laura Rossi, Giulio Zaniboni, Alberto Life (Basel) Review In recent years, precision medicine has taken an increasing place in various branches of medical oncology, including colorectal cancer. Among the potentially relevant mutations for this cancer is the KRAS mutation, initially defined as “untargetable”; today, we see the birth of new molecules that target one of the variants of the KRAS mutation, KRAS G12C, having a significant impact on the therapeutic options for other malignancies, such as metastatic lung cancer. This fundamental step forward has stimulated scientific research on other potential targets of KRAS, both indirect and direct, and combination treatments aiming to overcome the mechanisms of resistance to these drugs that decrease in efficacy in colorectal cancer. What was once a negative predictive marker of response to anti-EGFR drugs today has become a potential target for targeted treatments. In turn, the prognostic role of the mutation has become extremely interesting, making it a potentially useful element in therapeutic decision-making, not only regarding oncological treatments but also in a more complex and complete manner within a global vision of the patient, involving other figures on the multidisciplinary team, such as surgeons, radiotherapists, and interventional radiologists. MDPI 2023-01-31 /pmc/articles/PMC9967356/ /pubmed/36836752 http://dx.doi.org/10.3390/life13020395 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Cherri, Sara
Melocchi, Laura
Gandolfi, Laura
Rossi, Giulio
Zaniboni, Alberto
Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
title Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
title_full Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
title_fullStr Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
title_full_unstemmed Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
title_short Integrated Decision-Making in the Treatment of Colon-Rectal Cancer: The Case of KRAS-Mutated Tumors
title_sort integrated decision-making in the treatment of colon-rectal cancer: the case of kras-mutated tumors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9967356/
https://www.ncbi.nlm.nih.gov/pubmed/36836752
http://dx.doi.org/10.3390/life13020395
work_keys_str_mv AT cherrisara integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors
AT melocchilaura integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors
AT gandolfilaura integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors
AT rossigiulio integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors
AT zanibonialberto integrateddecisionmakinginthetreatmentofcolonrectalcancerthecaseofkrasmutatedtumors